Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46,656 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial.
Han B, Feinstein T, Shi Y, Chen G, Yao Y, Hu C, Shi J, Feng J, Wu H, Cheng Y, Guo QS, Jie Z, Ye F, Zhang Y, Liu Z, Mao W, Zhang L, Lu J, Zhao J, Bazhenova L, Ruiz J, Kloecker GH, Sujith KR, Oliff IA, Wong M, Liu B, Wu Y, Huang L, Sun Y; DUBLIN-3 study group. Han B, et al. Among authors: wu y, wu h. Lancet Respir Med. 2024 Oct;12(10):775-786. doi: 10.1016/S2213-2600(24)00178-4. Epub 2024 Sep 9. Lancet Respir Med. 2024. PMID: 39265599 Clinical Trial.
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial.
Chu T, Lu J, Bi M, Zhang H, Zhuang W, Yu Y, Shi J, Chen Z, Zhang X, Guo Q, Liu Q, Wu H, Fang J, Hu Y, Wang X, Han C, Li K, Han B. Chu T, et al. Among authors: wu h. Cancer Biol Med. 2021 Mar 12;18(3):816-24. doi: 10.20892/j.issn.2095-3941.2020.0212. Online ahead of print. Cancer Biol Med. 2021. PMID: 33710815 Free PMC article.
Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial.
Zhang C, Chen J, Wu H, Wang J, Gao L, Zhao J, Sun Y, Jia Z, Mu X, Bai C, Wang R, Wu K, Liu Q, Shi Y. Zhang C, et al. Among authors: wu h, wu k. Cancer Pathog Ther. 2024 Feb 7;2(4):268-275. doi: 10.1016/j.cpt.2024.02.001. eCollection 2024 Oct. Cancer Pathog Ther. 2024. PMID: 39371104 Free PMC article.
46,656 results
You have reached the last available page of results. Please see the User Guide for more information.